Immune Dysregulation in Acute SARS-CoV-2 Infection

Area of Science:

• Immunology
• Virology
• Infectious Diseases

Background:

• Neutralizing antibodies against SARS-CoV-2 spike protein are crucial for humoral immunity.
• Cytokine release drives the immune response during acute COVID-19 infection.
• Understanding antibody response in correlation with inflammation is key for managing disease severity.

Purpose of the Study:

• To evaluate antibody quantity and function across different COVID-19 disease severities.
• To analyze inflammatory and coagulation pathways associated with antibody response.
• To identify acute markers correlating with antibody production following SARS-CoV-2 infection.

Main Methods:

• Analysis of 230 plasma samples from 181 patients with varying COVID-19 severity.
• Utilized MesoScale Discovery (MSD) platform for measuring antibody concentration and ACE2 blocking function.
• Assessed plasma cytokines and soluble proinflammatory markers.

Main Results:

• Antibody quantity strongly correlated with the ability to block SARS-CoV-2 binding to ACE2.
• Significant positive correlation found between proinflammatory markers (ICAM, IL-1β, IL-4, IL-6, TNFα, Syndecan) and antibody quantity.
• No significant association between autoantibodies against type 1 interferon and disease severity.

Conclusions:

• Proinflammatory markers (IL-6, TNFα, IL-1β, ICAM, IL-4, Syndecan) are correlative of COVID-19 disease severity.
• These inflammatory markers also correlate with the quantity and quality of antibodies produced post-SARS-CoV-2 infection.
• Findings highlight the interplay between inflammation and adaptive immunity in COVID-19.